Truist Starts Vertex Coverage
Truist initiates coverage of Vertex with a buy rating, citing potential in kidney drugs. This may impact Vertex's stock price.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.